---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059829"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:03:48.057746+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals prices $75M public offering of common stock at $39.50 per share

## Summary
- Offering of 1,898,735 shares at $39.50/share; gross proceeds ~$75M before expenses.
- Underwriter granted 30-day option to purchase up to 284,810 additional shares.
- Closing expected on or about May 16, 2023, subject to customary conditions.
- Guggenheim Securities is lead book-running manager; Truist Securities also book-runner; H.C. Wainwright lead manager.

## SEC filing metadata
- accession: 0001104659-23-059829
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465923059829/0001104659-23-059829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465923059829/tm2315239d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059829
- JSON: https://secwatch.observer/filing/0001104659-23-059829.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059829.txt

## Key facts
- Material Agreements
  ANI PHARMACEUTICALS INC entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $75 million (effective 2023-05-11).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Guggenheim Securities, LLC
  - Value: approximately $75 million
  - Effective: 2023-05-11
  source text: On May 11, 2023, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 1,898,735 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $39.50 per share, for aggregate gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Guggenheim Securities, LLC (the “Underwriter”), the Company granted to the Underwriter a 30-day option to purchase up to an additional 284,810 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465923059829/0001104659-23-059829-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.